A new scientific review concludes that acidic cannabinoids including THCA, CBDA and CBGA are pharmacologically active compounds with potential therapeutic relevance across a range of brain disorders.
The review, published yesterday in Neuroscience and Biobehavioral Reviews, examined research on acidic cannabinoids in epilepsy, anxiety, depression, psychosis-related conditions and neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
Unlike THC and CBD, acidic cannabinoids are the forms naturally produced by the marijuana plant before heat, light or prolonged storage causes decarboxylation. The researchers said these compounds should not simply be viewed as inactive precursors to THC, CBD and other neutral cannabinoids.
Instead, THCA, CBDA, CBGA and related compounds appear to interact with a broad range of biological targets, including serotonin receptors, PPARγ receptors and ion channels, while influencing neuroinflammation, oxidative stress, mitochondrial function, calcium regulation and neurotrophic signaling.
Evidence was particularly notable for epilepsy. CBDA increased resistance to hyperthermia-induced seizures in a mouse model of Dravet syndrome, while CBGA has demonstrated anticonvulsant activity and enhanced the effects of the antiseizure medication clobazam in some experiments. However, THCA and CBGA have produced both anticonvulsant and proconvulsant effects depending on the dose and experimental model.
For psychiatric conditions, CBDA and the more chemically stable CBDA derivative CBDA-ME produced antidepressant-like and anxiety-reducing effects in several rodent studies. Researchers said CBDA’s anxiety-related effects appeared especially pronounced under conditions of stress rather than in animals under normal baseline conditions, with serotonin 5-HT1A signaling appearing to play an important role.
Preclinical Alzheimer’s research also found that CBDA and THCA improved learning and memory in mice while reducing markers including beta-amyloid and phosphorylated tau. Other studies found CBDA improved synaptic function, while CBDA and CBGA inhibited enzymes involved in the breakdown of acetylcholine and production of beta-amyloid.
THCA reduced neurodegeneration, inflammation and motor impairment in a mouse model relevant to Huntington’s disease. In an ALS mouse model, CBDA improved motor coordination and reduced neuronal loss, gliosis and inflammatory activity. The review notes that CBDA was the most effective of several cannabinoids tested in that experiment and showed greater efficacy than riluzole, an approved ALS medication.
Despite the findings, the authors emphasized that translating them to humans remains a major challenge. Acidic cannabinoids can be chemically unstable, generally have limited brain penetration and may behave differently depending on dose, formulation and route of administration.
Most importantly, the researchers found no randomized controlled trials evaluating purified acidic cannabinoids in patients with neurological, psychiatric or neurodegenerative disorders. They also found no ongoing interventional clinical trials specifically testing purified THCA, CBDA or CBGA for those conditions.
The authors conclude by stating:
Acidic cannabinoids represent an emerging class of bioactive compounds with distinct pharmacological properties that differentiate them from their neutral counterparts. Rather than acting primarily through CB1 receptor-mediated mechanisms, these molecules engage a diverse set of targets, including serotonergic receptors, PPARγ, ion channels, and signaling pathways involved in Ca2+ homeostasis, mitochondrial function, neuroinflammation, and neurotrophic regulation. This multitarget profile positions acidic cannabinoids as potentially valuable modulators of complex and multifactorial brain disorders.
Preclinical evidence supports their potential efficacy across a range of neurological and psychiatric conditions, including epilepsy, affective disorders, psychosis-related phenotypes, and neurodegenerative diseases. However, these effects are highly context-dependent and influenced by factors such as compound identity, dose, formulation, and experimental model. At present, the evidence remains predominantly preclinical, and key questions regarding pharmacokinetics, brain penetration, mechanism of action, and long-term safety are unresolved.
Advances in analytical chemistry, drug delivery and artificial intelligence provide new opportunities to address these challenges by improving compound stability, optimizing pharmacokinetic profiles, and accelerating target discovery. Nevertheless, substantial work is required to establish causal mechanisms, validate findings across models, and translate preclinical observations into clinically meaningful outcomes.
Overall, acidic cannabinoids should not be viewed simply as precursors of neutral cannabinoids, but as pharmacologically distinct entities with unique therapeutic potential. Realizing this potential will depend on the development of rigorous, integrated, and translationally oriented research strategies capable of bridging the gap between experimental pharmacology and clinical application.
